目次

le of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.2.3. Route Of Administration
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Antisense & RNAi Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Presence of strong product pipeline
3.2.1.2. Introduction of technological advancements in drug delivery
3.2.1.3. Implementation of favorable government initiatives & external funding for R&D activities
3.2.1.4. Rising collaborations between pharmaceutical companies
3.2.2. Market restraint analysis
3.2.2.1. Expensive and tedious research programs
3.2.2.2. Delivery of RNAi therapeutics and off-target effects
3.3. Antisense & RNAi Therapeutics Market Analysis Tools
3.3.1. Industry analysis - Porter’s
3.3.2. PESTEL analysis
3.3.3. COVID-19 impact analysis

Chapter 4. Antisense & RNAi Therapeutics Market: Technology Estimates & Trend Analysis
4.1. Technology Market Movement Analysis, 2023 & 2030
4.2. RNA Interference
4.2.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million)
4.3. Antisense RNA
4.3.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antisense & RNAi Therapeutics Market: Application Estimates & Trend Analysis
5.1. Application Market Movement Analysis, 2023 & 2030
5.2. Ocular
5.2.1. Ocular market estimates and forecasts 2018 to 2030 (USD Million)
5.3. Cardio metabolic & Renal Disorders
5.3.1. Cardio metabolic & renal disorders market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Cancer
5.4.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Neurodegenerative Disorders
5.5.1. Neurodegenerative Disorders Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Genetic Disorders
5.6.1. Genetic Disorders Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Infectious Diseases
5.7.1. Infectious Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Skin Diseases
5.8.1. Skin Diseases Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antisense & RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis
6.1. Route of Administration Movement Analysis, 2023 & 2030
6.2. Intravenous Injections
6.2.1. Intravenous Injections Market estimates and forecasts 2018 to 2030 (USD million)
6.3. Intrathecal Injections
6.3.1. Intrathecal Injections Market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Subcutaneous Injections
6.4.1. Subcutaneous Injections Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Other Delivery Methods
6.5.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antisense & RNAi Therapeutics Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. North America
7.2.1. U.S.
7.2.1.1. Key country dynamics
7.2.1.2. Regulatory framework
7.2.1.3. Competitive scenario
7.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.2.2. Canada
7.2.2.1. Key country dynamics
7.2.2.2. Regulatory framework
7.2.2.3. Competitive scenario
7.2.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3. Europe
7.3.1. UK
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework
7.3.1.3. Competitive scenario
7.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Germany
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework
7.3.2.3. Competitive scenario
7.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. France
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework
7.3.3.3. Competitive scenario
7.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.3.4. Italy
7.3.4.1. Key country dynamics
7.3.4.2. Regulatory framework
7.3.4.3. Competitive scenario
7.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.3.5. Spain
7.3.5.1. Key country dynamics
7.3.5.2. Regulatory framework
7.3.5.3. Competitive scenario
7.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.3.6. Norway
7.3.6.1. Key country dynamics
7.3.6.2. Regulatory framework
7.3.6.3. Competitive scenario
7.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.3.7. Sweden
7.3.7.1. Key country dynamics
7.3.7.2. Regulatory framework
7.3.7.3. Competitive scenario
7.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key country dynamics
7.3.8.2. Regulatory framework
7.3.8.3. Competitive scenario
7.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Japan
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework
7.4.1.3. Competitive scenario
7.4.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. China
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework
7.4.2.3. Competitive scenario
7.4.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. India
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework
7.4.3.3. Competitive scenario
7.4.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Australia
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework
7.4.4.3. Competitive scenario
7.4.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework
7.4.5.3. Competitive scenario
7.4.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework
7.4.6.3. Competitive scenario
7.4.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Latin America
7.5.1. Brazil
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework
7.5.1.3. Competitive scenario
7.5.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Mexico
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.6. MEA
7.6.1. South Africa
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework
7.6.1.3. Competitive scenario
7.6.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. UAE
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. Company Profiles/Listing
8.4.1. Olix Pharmaceuticals
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. GSK plc
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Sanofi
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Alnylam Pharmaceuticals, Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Ionis Pharmaceuticals, Inc.
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Benitec Biopharma Inc
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Silence Therapeutics
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Arbutus Biopharma
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Sarepta Therapeutics
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Percheron Therapeutics Limited
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives

List of Tables
Table 1 List of abbreviation
Table 2 Global antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
Table 3 Global antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 4 Global antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 5 Global antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 6 North America antisense & RNAi therapeutics market, by country, 2018 - 2030 (USD Million)
Table 7 North America antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 8 North America antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 9 North America antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 10 U.S. antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 11 U.S. antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 12 U.S. antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 13 Canada antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 14 Canada antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 15 Canada antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 16 Europe antisense & RNAi therapeutics market, by country, 2018 - 2030 (USD Million)
Table 17 Europe antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 18 Europe antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 19 Europe antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 20 Germany antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 21 Germany antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 22 Germany antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 23 UK antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 24 UK antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 25 UK antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 26 France antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 27 France antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 28 France antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 29 Italy antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 30 Italy antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 31 Italy antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 32 Spain antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 33 Spain antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 34 Spain antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 35 Denmark antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 36 Denmark antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 37 Denmark antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 38 Sweden antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 39 Sweden antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 40 Sweden antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 41 Norway antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 42 Norway antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 43 Norway antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 44 Asia Pacific antisense & RNAi therapeutics market, by country, 2018 - 2030 (USD Million)
Table 45 Asia Pacific antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 46 Asia Pacific antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 47 Asia Pacific antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 48 China antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 49 China antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 50 China antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 51 Japan antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 52 Japan antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 53 Japan antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 54 India antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 55 India antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 56 India antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 57 South Korea antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 58 South Korea antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 59 South Korea antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 60 Australia antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 61 Australia antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 62 Australia antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 63 Thailand antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 64 Thailand antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 65 Thailand antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 66 Latin America antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 67 Latin America antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 68 Latin America antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 69 Brazil antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 70 Brazil antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 71 Brazil antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 72 Mexico antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 73 Mexico antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 74 Mexico antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 75 Argentina antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 76 Argentina antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 77 Argentina antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 78 MEA antisense & RNAi therapeutics market, by country, 2018 - 2030 (USD Million)
Table 79 MEA antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 80 MEA antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 81 MEA antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 82 South Africa antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 83 South Africa antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 84 South Africa antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
Table 88 UAE antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
Table 89 UAE antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 90 UAE antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot-1
Fig. 14 Segment snapshot-2
Fig. 15 Competitive landscape snapshot
Fig. 16 Market trends & outlook
Fig. 17 PESTEL analysis
Fig. 18 Porter’s five forces analysis
Fig. 19 Antisense & RNAi therapeutics market: Technology outlook and key takeaways
Fig. 20 Antisense & RNAi therapeutics market: Technology movement analysis
Fig. 21 RNA interference market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Antisense RNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Antisense & RNAi therapeutics market: Application outlook and key takeaways
Fig. 24 Antisense & RNAi therapeutics market: Application movement analysis
Fig. 25 Ocular market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Cardiometabolic & renal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Skin diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Neurodegenerative disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Genetic disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Antisense & RNAi therapeutics market: Route of administration outlook and key takeaways
Fig. 33 Antisense & RNAi therapeutics market: Route of administration movement analysis
Fig. 34 Intravenous injections market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Intrathecal injections market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Subcutaneous injections market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Other delivery methods market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Regional marketplace outlook, 2023 & 2030, (USD million)
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 North America antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Key country dynamics
Fig. 42 U.S. antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Europe antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 UK antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 Germany antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 France antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Spain antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 Italy antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Denmark antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Key country dynamics
Fig. 57 Sweden antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Key country dynamics
Fig. 59 Norway antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Asia Pacific antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Japan antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 China antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Key country dynamics
Fig. 66 India antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Key country dynamics
Fig. 68 Australia antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Thailand antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Key country dynamics
Fig. 72 South Korea antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Latin America antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Brazil antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Mexico antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Key country dynamics
Fig. 79 Argentina antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 MEA antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 South Africa antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Key country dynamics
Fig. 84 Saudi Arabia antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Key country dynamics
Fig. 86 UAE antisense & RNAi therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Market participant categorization
Fig. 88 Global antisense & RNAi therapeutics market position analysis, 2023
Fig. 89 Strategic framework